Possibility of age regulation of the natriuretic peptide C-receptor in human platelets
暂无分享,去创建一个
M. Andreassi | D. Giannessi | A. Clerico | S. Ry | M. Colombo | N. Dini
[1] M. Yamauchi,et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] G. Sagnella. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. , 1998, Clinical science.
[3] H. Itoh,et al. Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. , 1998, Clinical chemistry.
[4] P. Poole‐Wilson,et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.
[5] J. Regnard,et al. Characterization of human platelet receptors for atrial natriuretic peptide: evidence for clearance receptors. , 1996, Cellular and Molecular Biology.
[6] F. Rengo,et al. Effects of age on the role of atrial natriuretic factor in renal adaptation to physiologic variations of dietary salt intake. , 1996, Journal of the American Society of Nephrology : JASN.
[7] J. Piletz,et al. Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. , 1996, Journal of psychiatric research.
[8] J. de Champlain,et al. C‐type natriuretic peptide and brain natriuretic peptide inhibit adenylyl cyclase activity: interaction with ANF‐R2/ANP‐C receptors , 1995, FEBS letters.
[9] R. Ziegler,et al. C-type natriuretic peptide neuromodulates via "clearance" receptors. , 1995, The American journal of physiology.
[10] G. Gauquelin,et al. Transient downregulation of glomerular atrial natriuretic factor receptors in high output heart failure in the rat. , 1995, Cardiovascular Research.
[11] D. Schocken,et al. Three Peptides From the Atrial Natriuretic Factor Prohormone Amino Terminus Lower Blood Pressure and Produce Diuresis, Natriuresis, and/or Kaliuresis in Humans , 1994, Circulation.
[12] D. Gardner. Molecular biology of the natriuretic peptides. , 1994, Trends in cardiovascular medicine.
[13] J. Regnard,et al. Atrial natriuretic factor receptors on human platelets. , 1994, Cellular and Molecular Biology.
[14] R. Giorgino,et al. Reduced effectiveness of atrial natriuretic factor in pre-menopausal obese women. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[15] M. Anand-Srivastava,et al. Atrial natriuretic factor receptors and signal transduction mechanisms. , 1993, Pharmacological reviews.
[16] L. Campbell,et al. The platelet angiotensin II receptor in type I diabetes: studies in patients with and without nephropathy , 1993, European journal of clinical investigation.
[17] M. Anand-Srivastava. Differential regulation of ANF-R2 receptors coupled to adenylyl cyclase in cardiovascular tissues in hypertension. , 1993, American journal of hypertension.
[18] E. Levin,et al. Natriuretic peptide C-receptor: more than a clearance receptor. , 1993, The American journal of physiology.
[19] H. Ruskoaho. Atrial natriuretic peptide: synthesis, release, and metabolism. , 1992, Pharmacological reviews.
[20] M. Brown,et al. Natriuretic peptide receptor mRNAs in the rat and human heart. , 1992, The Journal of clinical investigation.
[21] B. Myers,et al. Regulation of platelet clearance receptors for atrial natriuretic peptide in diabetic nephropathy. , 1992, Journal of the American Society of Nephrology : JASN.
[22] M. Currie,et al. Inhibition of endothelial cell clearance of atrial natriuretic peptide by cyclic GMP treatment. , 1992, Biochemical and biophysical research communications.
[23] S. Lightman,et al. Plasma atrial natriuretic peptide concentration and platelet atrial natriuretic peptide binding site density in ageing and hypertension. , 1991, Clinical science.
[24] M. Cantin,et al. The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system. , 1991, The Biochemical journal.
[25] M. Currie,et al. Cyclic GMP down-regulates atrial natriuretic peptide receptors on cultured vascular endothelial cells. , 1991, The Journal of biological chemistry.
[26] J. Wei,et al. Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans. , 1991, American journal of hypertension.
[27] H. De León,et al. Regulation of glomerular atrial natriuretic factor receptor subtypes by renal sympathetic nerves. , 1991, The American journal of physiology.
[28] E. Schiffrin,et al. Solubilization and molecular characterization of the atrial natriuretic peptide (ANP) receptor in human platelets: comparison with ANP receptors in rat tissues. , 1991, The Journal of clinical endocrinology and metabolism.
[29] M. Cantin,et al. Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. , 1990, The Journal of biological chemistry.
[30] H. Motulsky,et al. Calculating receptor number from binding experiments using same compound as radioligand and competitor. , 1989, Trends in pharmacological sciences.
[31] T. Strom,et al. Effects of a bolus dose of atrial natriuretic factor in young and elderly volunteers , 1989, European journal of clinical investigation.
[32] F. Murad,et al. Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells. , 1989, Biochimica et biophysica acta.
[33] T. Strom,et al. Binding sites for atrial natriuretic peptide on platelets in patients with congestive cardiomyopathy , 1988, European journal of clinical investigation.
[34] E. Schiffrin,et al. Platelet binding sites and plasma concentration of atrial natriuretic peptide in patients with essential hypertension. , 1988, Journal of hypertension.
[35] E. Schiffrin,et al. Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure. , 1988, Clinical science.
[36] A. Kenny,et al. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. , 1987, The Biochemical journal.
[37] E. Schiffrin,et al. Platelet Binding Sites for Atrial Natriuretic Factor in Humans: Characterization and Effects of Sodium Intake , 1986, Hypertension.
[38] E. Schiffrin,et al. Cyclic GMP as mediator and biological marker of atrial natriuretic factor. , 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[39] R. Cuneo,et al. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. , 1986, Life sciences.
[40] A. D. de Bold,et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.
[41] H. Motulsky,et al. Characterization of α2-adrenergic receptors on human platelets using [3H]yohimbine , 1980 .
[42] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[43] C. Frampton,et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. , 1993, The Journal of clinical endocrinology and metabolism.
[44] K. Hosoda,et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. , 1992, Endocrinology.